Blockade of p38 MAPK inhibits chronic allograft vasculopathy

Transplantation

Volumn 85, Issue 2, 2008, Pages 293-297

  Öllinger, Robert ^a   Thomas, Michael ^a,b   Kogler, Pamela ^a   Hermann, Martin ^a   Weiss, Helmut ^a   Mark, Walter ^a   Bilban, Martin ^b,c   Troppmair, Jakob ^a   Bach, Fritz H ^b   Margreiter, Raimund ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic rejection; Mitogen activated protein kinases; Vascular smooth muscle cells; Vasculopathy

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CHRONIC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DATA ANALYSIS; ENZYME INHIBITION; HYPOTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; AORTA; GRAFT SURVIVAL; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIMIDINES; RATS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 38549149198     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318160130f     Document Type: Article

References (38)

1. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, R TB, Dyke DB. Immunosuppression: Practice and trends. Am J Transplant 2004; 4(Suppl 9): 38.
2. Hayry P, Isoniemi H, Yilmaz S, et al. Chronic allograft rejection. Immunol Rev 1993; 134: 33.
3. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6: 1248.
4. Lattmann T, Hein M, Horber S, et al. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: Role of endothelin receptor signaling. Am J Transplant 2005; 5: 1042.
5. Csencsits K, Wood SC, Lu G, et al. Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am J Transplant 2006; 6: 959.
6. Methe H, Zimmer E, Grimm C, Nabauer M, Koglin J. Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004; 78: 1324.
7. Atkinson C, Horsley J, Rhind-Tutt S, et al. Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. J Heart Lung Transplant 2004; 23: 427.
8. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411.
9. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738.
10. Hu Y, Davison F, Ludewig B, et al. Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circulation 2002; 106: 1834.
11. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320.
12. Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717.
13. Clanachan AS, Jaswal JS, Gandhi M, et al. Effects of inhibition of myocardial extracellular-responsive kinase and P38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia. Transplantation 2003; 75: 173.
14. Yoshinari D, Takeyoshi I, Kobayashi M, et al. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to university of Wisconsin solution on reperfusion injury in liver transplantation. Transplantation 2001; 72: 22.
15. Kanda Y, Nishio E, Kuroki Y, Mizuno K, Watanabe Y. Thrombin activates p38 mitogen-activated protein kinase in vascular smooth muscle cells. Life Sci 2001; 68: 1989.
16. Ollinger R, Bilban M, Erat A, et al. Bilirubin: A natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005; 112: 1030.
17. Ju H, Nerurkar S, Sauermelch CF, et al. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther 2002; 301: 15.
18. Zhan Y, Kim S, Izumi Y, et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 2003; 23: 795.
19. Kesherwani V, Sodhi A. Quantitative role of p42/44 and p38 in the production and regulation of cytokines TNF-alpha, IL-1beta and IL-12 by murine peritoneal macrophages in vitro by concanavalin A. Cytokine 2007; 37: 62.
20. Sherry CL, O'Connor JC, Kramer JM, Freund GG. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 MAPK. J Immunol 2007; 178: 663.
21. Dietrich H, Hu Y, Zou Y, et al. Mouse model of transplant arteriosclerosis: Role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 2000; 20: 343.
22. Solway J, Seltzer J, Samaha FF, et al. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha J Biol Chem 1995; 270: 13460.
23. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation 2005; 80: 1641.
24. van Loosdregt J, van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 2006; 114: 1599.
25. Ono K, Han J. The p38 signal transduction pathway: Activation and function. Cell Signal 2000; 12: 1.
26. Ward KW, Proksch JW, Azzarano LM, et al. SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res 2001; 18: 1336.
27. Koike N, Takeyoshi I, Ohki S, Tokumine M, Morishita Y. The comparison of mitogen-activated protein kinases that become activated within the left ventricular and right atrial tissues following heart transplantation in canine model. J Invest Surg 2007; 20: 105.
28. Liang T, Xu S, Yu J, Shen K, Li D, Zheng S. Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transpl 2005; 11: 1527.
29. Tatekawa Y, Kanehiro H, Dohi Y, et al. Intragraft expression of p38 and activated p38 MAPK (mitogen-activated protein kinase) in rat small bowel transplantation. Transpl Int 2001; 14: 211.
30. Zhang X, Cao Y, Meng A, Bai Y. Graft expression of p38 and tumor necrosis factor-alpha in heart transplantation in rats. Prog Transplant 2002; 12: 309.
31. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, Foxwell BM. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 1997; 272: 15023.
32. Ollinger R, Yamashita K, Bilban M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 2007; 6: 39.
33. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730.
34. Kishore R, Luedemann C, Bord E, Goukassian D, Losordo DW. Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: Differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways. Circ Res 2003; 93: 932.
35. Bojakowski K, Religa P, Bojakowska M, Hedin U, Gaciong Z, Thyberg J. Arteriosclerosis in rat aortic allografts: Early changes in endothelial integrity and smooth muscle phenotype. Transplantation 2000; 70: 65.
36. Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis 1997; 40: 107.
37. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325.
38. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Invest Drugs 2004; 5: 1205.